AC220
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Acute
Conditions
Leukemia, Myeloid, Acute
Trial Timeline
Apr 1, 2012 → Mar 1, 2015
NCT ID
NCT01565668About AC220
AC220 is a phase 2 stage product being developed by Daiichi Sankyo for Leukemia, Myeloid, Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT01565668. Target conditions include Leukemia, Myeloid, Acute.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Acute were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02675478 | Phase 1 | Completed |
| NCT01565668 | Phase 2 | Completed |
| NCT01468467 | Phase 1 | Completed |
| NCT00462761 | Phase 1 | Completed |
Competing Products
20 competing products in Leukemia, Myeloid, Acute